Vabysmo (Faricimab-Svoa) for AMD

Overview
Vabysmo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD). It’s prescribed for people who’ve developed abnormal blood vessels in the macula, leading to vision loss. Vabysmo is also known by its drug name, faricimab-svoa.

Vabysmo is a biologic drug that inhibits two proteins called vascular endothelial growth factor and angiopoietin-2. Scientists believe that Vabysmo works by reducing the growth of abnormal blood vessels and stabilizing blood vessels to improve vision in people with wet AMD.

How do I take it?
Prescribing information states that Vabysmo is given as an injection into the eye. Typically, the dosing schedule is once every four weeks for the first four doses. After that, the injection schedule varies based on how the person responds to treatment. Vabysmo must be given by a qualified health care provider.

Side effects
Common side effects of Vabysmo include bleeding on the surface of the eye, floaters (spots in vision), a tear in the retina, increased inflammation or pressure inside the eye, eye pain or irritation, an unpleasant sensation (itching, burning, or grittiness), and bleeding in the eye.

Rare but serious side effects may include endophthalmitis (severe eye infection), retinal detachment (separation of the retina from the back of the eye), and blood clots that block arteries. 

For more information about this treatment, visit:

Label: Vabysmo — Faricimab Injection, Solution — DailyMed

Vabysmo — Genentech